Loading clinical trials...
Loading clinical trials...
A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease
This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.
Age
29 - No limit years
Sex
ALL
Healthy Volunteers
No
Huntington Study Group
Rochester, New York, United States
Start Date
July 1, 2007
Primary Completion Date
June 1, 2008
Completion Date
June 1, 2008
Last Updated
June 8, 2015
91
ACTUAL participants
Placebo
OTHER
Dimebon
DRUG
Lead Sponsor
Medivation, Inc.
Collaborators
NCT02855476
NCT04120493
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05107128